Eurobio Scientific: all resolutions approved at the Annual General Meeting

Eurobio Scientific: all resolutions approved at the Annual General Meeting

The Board of Directors appoints a new governance

Paris, 16 June 2023 – 5:45pm

Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro specialty medical diagnostics and life sciences, held its ordinary and extraordinary general meeting of shareholders on 13 June 2023.

At the date of the meeting, the total number of shares with voting rights was 10,208,224 for an equivalent total number of voting rights. The 73 shareholders present, represented or voting by post at this General Meeting, together held 5,156,579 shares, giving a quorum of 50.51%, for the resolutions submitted to the Ordinary and Extraordinary General Meetings.

All the resolutions approved by the Board of Directors, both ordinary and extraordinary, were adopted by a very large majority, in particular :

• approval of the annual and consolidated financial statements for the year ended 31 December 2022,
• the appropriation of net profit for the 2022 financial year,
• the authorisation given to the Board of Directors to implement a share buyback programme,
• renewal of the financial authorisations granted to the Board of Directors to carry out capital increases while maintaining and/or cancelling shareholders' pre-emptive subscription rights,
• renewal of the authorisation given to the Board of Directors to cancel shares previously bought back under the share buyback programme,
• renewal of the authorisation given to the Board of Directors to grant free shares to employees and officers of the Company.

Voting details are provided in the appendix on the next page.

At the Board meeting held after the Annual General Meeting, the directors also agreed to change the Company's governance structure with :

• the appointment of Denis Fortier as Chairman and CEO
• the appointment of three Deputy CEOs:
  • Jean-Michel Carle
  • Anne-Sophie Hérelle, Finance and Information Systems
  • Cathie Marsais, Operations and Regulatory Affairs
    
    

Hervé Duchesne de Lamotte, previously Deputy CEO, remains a director.

Appendix : voting details

Next financial meeting
H1 revenues: July 24, 2023 (after market closes)

Attachment

• 230616PR-Eurobio Scientific AG 2023_EN